In Brief: Chattem
This article was originally published in The Tan Sheet
Executive Summary
Chattem: U.S. sales increase 6% in fiscal 1995 (ended Nov. 30), led by the recently acquired pHisoderm skin care and Benzodent denture analgesic brands; a "significant gain" in Bullfrog sunscreens; and "strong demand" for Icy Hot analgesics, the firm says Jan. 26. Pamprin and Premsyn PMS menstrual products were flat and Flex-all analgesic sales were down. Chattem's international sales 14% jump was driven by pHisoderm in Canada and all major brands in Europe, the firm says. Consolidated sales rose 6.6% to $100.7 mil. in fiscal 1995. Net income was $12 mil., up from $2.1 mil. in FY 1994, and includes a $9.3 mil. gain from the disposal of the Specialty Chemicals division in May 1995. Income from operations increased 15.4% to $14.5 mil...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning